Author:
Dhamodharan Shankar,Rose Mathew Maria,Chakkarappan Sundaram Reddy,Umadharshini Karuppiah Vijayamuthuramalingam,Arulmurugan Ramalingam,Subbiah Shanmugam,Inoue Ituro,Munirajan Arasambattu Kannan
Abstract
AbstractTyrosine kinase inhibitor is an effective chemo-therapeutic drug against tumors with deregulated EGFR pathway. Recently, a genetic variant rs10251977 (G>A) in exon 20 of EGFR reported to act as a prognostic marker for HNSCC. Genotyping of this polymorphism in oral cancer patients showed a similar frequency in cases and controls. EGFR-AS1 expressed significantly high level in tumors and EGFR-A isoform expression showed significant positive correlation (r = 0.6464, p < 0.0001) with reference to EGFR-AS1 expression levels, consistent with larger TCGA HNSCC tumor dataset. Our bioinformatic analysis showed enrichment of alternative splicing marks H3K36me3 and presence of intronic polyA sites spanning around exon 15a and 15b of EGFR facilitates skipping of exon 15b, thereby promoting the splicing of EGFR-A isoform. In addition, high level expression of PTBP1 and its binding site in EGFR and EGFR-AS1 enhances the expression of EGFR-A isoform (r = 0.7404, p < 0.0001) suggesting that EGFR-AS1 expression modulates the EGFR-A and D isoforms through alternative splicing. In addition, this polymorphism creates a binding site for miR-891b in EGFR-AS1 and may negatively regulate the EGFR-A. Collectively, our results suggested the presence of genetic variant in EGFR-AS1 modulates the expression of EGFR-D and A isoforms.
Funder
National Institute of Genetics
Department of Health Research, India
Publisher
Springer Science and Business Media LLC
Reference49 articles.
1. Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA 68, 394–424 (2018).
2. Bose, P., Brockton, N. T. & Dort, J. C. Head and neck cancer: From anatomy to biology. Int. J. Cancer 133, 2013–2023 (2013).
3. Arunkumar, G. et al. Expression profiling of long non-coding RNA identifies linc-RoR as a prognostic biomarker in oral cancer. Tumor Biol. 39, 1010428317698366 (2017).
4. Arunkumar, G. et al. Long non-coding RNA CCAT1 is overexpressed in oral squamous cell carcinomas and predicts poor prognosis. Biomed. Rep. 6, 455–462 (2017).
5. Elferink, L. A. & Resto, V. A. Receptor-tyrosine-kinase-targeted therapies for head and neck cancer. J. Signal Trans. 20, 11. https://doi.org/10.1155/2011/982879 (2011).
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献